This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

Diluent for Miochol E

POM
Read time: 1 mins
Last updated: 29 Nov 2019
...
 

Summary of product characteristics


1. Name of the medicinal product

Diluent for Miochol E


2. Qualitative and quantitative composition

Each ampoule contains 99.77 % water for injection.

For excipients see 6.1.


3. Pharmaceutical form

Solvent for use with Miochol-E 20mg powder for instillation solution for intraocular use. Clear, colourless solution.


4.1. Therapeutic indications

None


4.2. Posology and method of administration

For intraocular use.

Diluent for Miochol-E is given for intraocular use, after reconstitution.


4.3. Contraindications

Not Applicable


4.4. Special warnings and precautions for use

This medicine contains potassium, less than 1mmol (39mg) per 2ml dose. This medicine contains less than 1 mmol sodium (23mg) per 2ml dose.


4.5. Interaction with other medicinal products and other forms of interaction

Not Applicable


4.6. Fertility, pregnancy and lactation

Not Applicable


4.7. Effects on ability to drive and use machines

Not Applicable


4.8. Undesirable effects

Not Applicable


4.9. Overdose

Not Applicable


5.1. Pharmacodynamic properties

Pharmacotherapeutic group: solvents and diluting agents inc irrigation solutions, ATC code: V07AB


5.2. Pharmacokinetic properties

Not Applicable


5.3. Preclinical safety data

Each of the constituents are well established pharmacopoeial ingredients, so no further information is presented.


6.1. List of excipients

Calcium chloride dihydrate, magnesium chloride hexahydrate, potassium chloride, sodium acetate trihydrate.


6.2. Incompatibilities

Not Applicable


6.3. Shelf life

3 years

Following reconstitution with Miochol-E: 6 hours.


6.4. Special precautions for storage

No special precautions for storage.

Chemical and physical in-use stability has been demonstrated for 6 hours at 2-8°C or for 6 hours at 25°C

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would not normally be longer than 6 hours at 2-8°C or 6 hours at 25°C.


6.5. Nature and contents of container

Type 1 clear glass ampoule with filter.


6.6. Special precautions for disposal and other handling

See Summary of Product Characteristics for Miochol E


7. Marketing authorisation holder

Dr. Gerhard MannChem.-Pharm. Fabrik GmbHBrunsbuetteler Damm 165-17313581 Berlin

Germany


8. Marketing authorisation number(s)

PL13757/0018


9. Date of first authorisation/renewal of the authorisation

9 March 2011


10. Date of revision of the text

July 2012

4.1 Therapeutic indications

None

4.2 Posology and method of administration

For intraocular use.

Diluent for Miochol-E is given for intraocular use, after reconstitution.

4.3 Contraindications

Not Applicable

4.4 Special warnings and precautions for use

This medicine contains potassium, less than 1mmol (39mg) per 2ml dose. This medicine contains less than 1 mmol sodium (23mg) per 2ml dose.

4.5 Interaction with other medicinal products and other forms of interaction

Not Applicable

4.6 Fertility, pregnancy and lactation

Not Applicable

4.7 Effects on ability to drive and use machines

Not Applicable

4.8 Undesirable effects

Not Applicable

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).